查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953476

非鴉片類止痛藥市場－全球產業規模、佔有率、趨勢、機會和預測：按產品、治療用途、分銷管道、地區和競爭格局分類，2021-2031年

Non-Opioids Analgesics Drugs Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Products, Therapeutic Applications, Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球非鴉片類止痛藥市場預計將從 2025 年的 8.3632 億美元成長到 2031 年的 10.8349 億美元，複合年成長率為 4.41%。

這些藥物，包括對乙醯胺酚、非類固醇消炎劑（NSAIDs）和局部麻醉劑，能夠在不與鴉片受體相互作用的情況下緩解疼痛。由於慢性疼痛負擔日益加重，以及為緩解鴉片類藥物危機而採取的嚴格監管措施，這項特性變得愈發重要。美國醫學會（AMA）的數據也支持這種轉向更安全治療方案的趨勢。該機構預測，到2024年，全美鴉片類處方箋將比2012年下降51.7%，顯示人們正顯著轉向使用非鴉片類藥物。

市場概覽
預測期 2027-2031
市場規模：2025年 8.3632億美元
市場規模：2031年 10.8349億美元
複合年成長率：2026-2031年 4.41%
成長最快的細分市場 整形外科和肌肉骨骼疼痛
最大的市場 北美洲

儘管存在這些積極趨勢，但市場仍面臨與當前標準療法安全性相關的重大挑戰，尤其是長期使用帶來的心血管和消化器官系統風險。這些副作用限制了需要長期照護的患者的治療選擇，從而有效地縮小了潛在市場規模。此外，監管機構實施嚴格的證據標準，要求新化合物必須展現出卓越的安全性，這設定了很高的進入門檻，減緩了該領域新治療方法的引入和推廣。

市場促進因素

全球對無鴉片類藥物疼痛管理通訊協定的重視正從根本上重塑競爭格局。醫療系統正積極推行管理方案，以更安全的替代療法取代成癮性麻醉止痛藥。這一策略轉變促使藥物研發領域的資本投入激增，例如，Latigo Biotherapeutics公司在2024年2月完成的A輪資金籌措，籌集了1.35億美元，用於推進其下一代非鴉片類候選藥物的研發。這項投資旨在應對一項緊迫的臨床挑戰，進一步凸顯了開發有效、無成癮性治療方案的緊迫性。正如Vertex Pharmaceuticals公司在2024年7月的報告中所指出的，「美國每年約有8,000萬人需要服用急性疼痛藥物」。

同時，慢性疼痛和關節炎的日益普遍正在推動市場擴張，而全球人口老化加劇了這一趨勢，老年人更容易患上與老齡化相關的退化性肌肉骨骼疾病和神經病變疾病。這些疾病需要長期消化器官系統和傳統非類固醇消炎劑（NSAIDs）的胃腸道風險。 2024年11月《MedPage Today》的一篇報導引用的一項調查數據表明了這種需求的規模，該文章報告稱，2023年美國成年人中將有24.3%的人患有慢性疼痛。這確保了對能夠提供持久療效的創新止痛藥的持續需求。

市場挑戰

全球非鴉片類鎮痛藥市場成長的主要障礙在於現有標準療法長期使用所帶來的安全隱患。儘管臨床上迫切需要擺脫鴉片類藥物，但長期使用關鍵藥物類別（尤其非類固醇消炎劑)）已被證實存在嚴重的消化道出血和心血管事件風險，這限制了市場擴張。這些安全隱患迫使醫療機構嚴格限制劑量和處方療程，實際上將許多老年患者和合併其他疾病的患者排除在持續疼痛管理之外。這種做法人為地限制了市場規模，而限制因素並非療效需求，而是藥物毒性。

近期臨床證據進一步強化了這種限制性環境，凸顯了這些風險，並鼓勵謹慎用藥。例如，歐洲風濕病學會 (EARA) 在 2024 年報告稱，慢性病患者接受高劑量非類固醇抗發炎藥物 (NSAID) 治療會使心血管疾病風險增加 10%。這些數據不僅限制了病患的用藥途徑，也提高了參與企業的監管門檻，迫使他們投入大量成本來證明其新化合物相比現有風險具有更優的長期安全性。

市場趨勢

選擇性NaV1.8鈉通道阻斷劑的商業化正在建立新的臨床標準，其作用標靶為周邊疼痛訊號，同時避免了鴉片類藥物典型的中樞神經系統副作用。這項藥物創新直接滿足了市場對強效鎮痛藥的需求，既避免了麻醉性鎮痛藥的依賴性風險，也避免了傳統非類固醇抗發炎藥的出血風險。該類藥物的療效已得到患者良好療效的證實。根據Vertex Pharmaceuticals 2024年1月發布的新聞稿，在一項3期臨床研究中，83.2%的患者對選擇性NaV1.8抑制劑蘇澤曲啶（suzetridine）治療中重度急性疼痛的療效評價為「良好」、「非常好」或「極佳」。

同時，經皮和局部給藥系統正變得越來越受歡迎。它們能夠局部緩解疼痛，同時避免口服給藥帶來的全身毒性。醫療保健提供者越來越傾向於使用這些製劑治療神經病變疼痛和肌肉骨骼疾病，以降低前述的心血管和消化器官系統風險，有助於提高老年人的長期用藥依從性。 Scilex Holding Company 的Lidocaine局部給藥系統自 2024 年 2 月上市以來已治療超過一百萬名患者，其高普及率也印證了這一轉變。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球非鴉片類止痛藥市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品（醫用大麻、含薄荷醇、 Omega-3脂肪酸、肉毒桿菌、辣椒素衍生物）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美非鴉片類鎮痛藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲非鴉片類鎮痛藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區非鴉片類鎮痛藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲非鴉片類鎮痛藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲非鴉片類止痛藥市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球非鴉片類止痛藥市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Vertex Pharmaceuticals Inc.
  • Cadence Pharmaceuticals Inc.
  • Pacira Biosciences Inc.
  • Eli Lilly and Company
  • Centrexion Therapeutics Corp.
  • Biogen Inc.
  • Novartis AG
  • GSK PLC
  • Pfizer Inc.
  • Teikoku Seiyaku Co. Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23991

The Global Non-Opioids Analgesics Drugs Market is projected to expand from USD 836.32 Million in 2025 to USD 1083.49 Million by 2031, exhibiting a compound annual growth rate of 4.41%. These pharmacological agents, which include acetaminophen, NSAIDs, and local anesthetics, provide pain relief without interacting with opioid receptors, a characteristic that has become increasingly critical due to the rising burden of chronic pain and strict regulatory efforts to mitigate the opioid crisis. This shift toward safer therapeutic options is evidenced by data from the American Medical Association, which reported a 51.7% nationwide decrease in opioid prescriptions in 2024 compared to 2012 levels, indicating a significant migration toward non-opioid pharmacotherapies.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 836.32 Million
Market Size 2031USD 1083.49 Million
CAGR 2026-20314.41%
Fastest Growing SegmentOrthopedic and Musculoskeletal Pain
Largest MarketNorth America

Despite these positive drivers, the market encounters substantial hurdles related to the safety profiles of current standard treatments, particularly the cardiovascular and gastrointestinal risks associated with long-term use. These adverse effects constrain the therapeutic window for patients needing prolonged care, effectively limiting the total addressable market. Furthermore, regulatory bodies enforce rigorous evidentiary standards requiring new compounds to demonstrate superior safety, creating high barriers to entry that slow the introduction and expansion of novel therapies within the sector.

Market Driver

The competitive landscape is being fundamentally reshaped by a global emphasis on opioid-free pain management protocols, where healthcare systems are aggressively implementing stewardship programs to replace addictive narcotics with safer alternatives. This strategic pivot is fueling a surge in capital allocation for drug discovery, as highlighted by Latigo Biotherapeutics securing $135 million in Series A financing in February 2024 to advance next-generation non-opioid candidates. This investment addresses an urgent clinical gap, further underscored by a July 2024 Vertex Pharmaceuticals report noting that approximately 80 million people in the U.S. require acute pain medication annually, creating a critical imperative for effective, non-addictive therapeutic options.

Concurrently, the increasing prevalence of chronic pain and arthritic conditions serves as a demographic engine for market expansion, driven by an aging global population prone to degenerative musculoskeletal and neuropathic disorders. These conditions necessitate long-term pharmacological interventions that avoid the toxicity of opioids or the gastrointestinal risks of traditional NSAIDs. The scale of this demand is illustrated by surveillance data cited in a November 2024 MedPage Today article, which revealed that 24.3% of U.S. adults reported suffering from chronic pain in 2023, ensuring a continuous need for innovative analgesics capable of delivering sustained efficacy.

Market Challenge

A primary obstacle inhibiting the growth of the global non-opioid analgesics drugs market is the unfavorable safety profile linked to the chronic administration of existing standard-of-care treatments. While there is a clinical urgency to move away from opioids, market expansion is restricted because dominant drug classes, particularly NSAIDs, carry documented risks of severe gastrointestinal bleeding and cardiovascular events when used long-term. These safety concerns force providers to strictly limit dosage and prescription duration, effectively excluding a significant population of elderly and comorbid patients from consistent pain management, thereby artificially capping the market volume based on toxicity rather than efficacy demand.

This restrictive environment is reinforced by recent clinical evidence that highlights these risks and promotes cautious prescribing behaviors. For instance, the European Alliance of Associations for Rheumatology reported in 2024 that high-dose NSAID regimens were associated with a 10% increased risk of cardiovascular disease in patients treated for chronic conditions. Such data not only limits patient access but also elevates the regulatory barriers for new entrants, who must incur substantial costs to prove that their novel compounds offer superior long-term safety compared to these established risks.

Market Trends

The commercialization of selective NaV1.8 sodium channel blockers is establishing a new clinical standard by targeting peripheral pain signals while avoiding the central nervous system side effects typical of opioids. This pharmacological innovation directly addresses the market's need for potent analgesia that bypasses the addiction risks of narcotics and the bleeding liabilities of traditional NSAIDs. The viability of this class is supported by strong patient outcomes; according to a January 2024 Vertex Pharmaceuticals press release, 83.2% of patients in a Phase 3 study rated the selective NaV1.8 inhibitor suzetrigine as good, very good, or excellent for treating moderate-to-severe acute pain.

Simultaneously, the market is witnessing a proliferation of transdermal and topical drug delivery systems, which offer localized pain relief that circumvents the systemic toxicity associated with oral administration. Healthcare providers are increasingly favoring these formulations for neuropathic and musculoskeletal conditions to mitigate the cardiovascular and gastrointestinal risks mentioned previously, thereby supporting better long-term compliance in elderly populations. This shift is evidenced by significant adoption rates, such as Scilex Holding Company's February 2024 announcement that over one million patients have been treated with their lidocaine topical system since its launch.

Key Market Players

  • Vertex Pharmaceuticals Inc.
  • Cadence Pharmaceuticals Inc.
  • Pacira Biosciences Inc.
  • Eli Lilly and Company
  • Centrexion Therapeutics Corp.
  • Biogen Inc.
  • Novartis AG
  • GSK PLC
  • Pfizer Inc.
  • Teikoku Seiyaku Co. Ltd.

Report Scope

In this report, the Global Non-Opioids Analgesics Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Opioids Analgesics Drugs Market, By Products

  • Medical Cannabis
  • Menthol- Containing
  • Omega 3 Fatty Acid
  • Botulinum Toxins
  • Capsaicin Derived

Non-Opioids Analgesics Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Opioids Analgesics Drugs Market.

Available Customizations:

Global Non-Opioids Analgesics Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Opioids Analgesics Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Products (Medical Cannabis, Menthol- Containing, Omega 3 Fatty Acid, Botulinum Toxins, Capsaicin Derived)
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America Non-Opioids Analgesics Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Products
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Opioids Analgesics Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Products
    • 6.3.2. Canada Non-Opioids Analgesics Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Products
    • 6.3.3. Mexico Non-Opioids Analgesics Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Products

7. Europe Non-Opioids Analgesics Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Products
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Products
    • 7.3.2. France Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Products
    • 7.3.3. United Kingdom Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Products
    • 7.3.4. Italy Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Products
    • 7.3.5. Spain Non-Opioids Analgesics Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Products

8. Asia Pacific Non-Opioids Analgesics Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Products
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Products
    • 8.3.2. India Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Products
    • 8.3.3. Japan Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Products
    • 8.3.4. South Korea Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Products
    • 8.3.5. Australia Non-Opioids Analgesics Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Products

9. Middle East & Africa Non-Opioids Analgesics Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Products
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Opioids Analgesics Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Products
    • 9.3.2. UAE Non-Opioids Analgesics Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Products
    • 9.3.3. South Africa Non-Opioids Analgesics Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Products

10. South America Non-Opioids Analgesics Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Products
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Opioids Analgesics Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Products
    • 10.3.2. Colombia Non-Opioids Analgesics Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Products
    • 10.3.3. Argentina Non-Opioids Analgesics Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Products

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Opioids Analgesics Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Vertex Pharmaceuticals Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cadence Pharmaceuticals Inc.
  • 15.3. Pacira Biosciences Inc.
  • 15.4. Eli Lilly and Company
  • 15.5. Centrexion Therapeutics Corp.
  • 15.6. Biogen Inc.
  • 15.7. Novartis AG
  • 15.8. GSK PLC
  • 15.9. Pfizer Inc.
  • 15.10. Teikoku Seiyaku Co. Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer